Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 13/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491248 | 0.85 | DCTPP1 (0.38) | DCTPP1F2RL3MAPTL3MBTL1LMNA | |
| SCHEMBL6490602 | 0.85 | PPARG (0.41) | DCTPP1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL6488896 | 0.83 | DCTPP1 (0.40) | DCTPP1MAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6489346 | 0.82 | MRGPRX4 (0.46) | SMN1; SMN2 | |
| SCHEMBL6498814 | 0.81 | S1PR1 (0.39) | DCTPP1 | |
| SCHEMBL7196400 | 0.81 | PIK3C2B (0.40) | DCTPP1 | |
| SCHEMBL6490528 | 0.81 | DCTPP1 (0.42) | DCTPP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7200216 | 0.80 | PIK3C2B (0.41) | DCTPP1SMN1; SMN2 | |
| SCHEMBL6487408 | 0.80 | DCTPP1 (0.38) | DCTPP1MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6492577 | 0.80 | DCTPP1 (0.41) | DCTPP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | DCTPP1 1534/4885F2RL3 4305/4885MAPT 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.